CN112725403A - Blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method - Google Patents

Blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method Download PDF

Info

Publication number
CN112725403A
CN112725403A CN202110096896.8A CN202110096896A CN112725403A CN 112725403 A CN112725403 A CN 112725403A CN 202110096896 A CN202110096896 A CN 202110096896A CN 112725403 A CN112725403 A CN 112725403A
Authority
CN
China
Prior art keywords
bacteria
apoh
column
bacterial
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110096896.8A
Other languages
Chinese (zh)
Inventor
赵志军
周云花
杨宁爱
康宇婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital of Ningxia Medical University
Original Assignee
General Hospital of Ningxia Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital of Ningxia Medical University filed Critical General Hospital of Ningxia Medical University
Priority to CN202110096896.8A priority Critical patent/CN112725403A/en
Publication of CN112725403A publication Critical patent/CN112725403A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/10—Enterobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The application provides a blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitivity method, which comprises the following steps: single colonies were picked and grown overnight in medium and subjected to 12 gradient design to test OD of bacterial concentration625A value; diluting the buffer solution by using sterile deionized water to obtain a diluted buffer solution; incubating 20 mu L of ApoH magnetic beads, buffer solution and cultured colonies for 15min at the temperature of 37 ℃ by a bacteria culture shaker at 300rpm to obtain a bacteria-ApoH magnetic bead mixture; magnetic treatment of bacterium-ApoHCentrifuging the bead mixture at 4 ℃ and 12000rpm, discarding the supernatant and resuspending to obtain a bacterial suspension; putting the bacterial suspension on an MS separation column to pass through the column to obtain reaction liquid after passing through the column; the reaction solution was used to perform a 96-well plate fluorescence susceptibility test. When the method is used for detecting the pathogenic bacteria infected by the blood stream, the detection is carried out by utilizing the magnetic bead enrichment principle, and the detection sensitivity can be improved by enriching bacteria by the magnetic beads, so that the positive rate and the detectable rate of the detection are improved.

Description

Blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method
Technical Field
The application relates to the technical field of pathogenic microorganisms, in particular to a blood stream infection pathogenic negative bacteria trace broth fluorescence drug sensitization method.
Background
Blood Stream Infection (BSI) refers to a serious systemic infectious disease in which various pathogenic microorganisms (including bacteria, viruses or fungi) invade the blood, multiply in the blood and produce and release metabolites such as toxins, and induce cytokine release, causing systemic infection, poisoning and inflammatory reactions, and possibly even causing changes in the coagulation and fibrinolysis systems, resulting in systemic multiple organ dysfunction syndrome. Therefore, control of bloodstream infections is receiving increasing attention.
Generally, the blood stream infection is more dangerous, if the anti-infection treatment cannot be carried out in time, the prognosis is poorer, the morbidity and the mortality of clinical patients can be increased, and researches show that the early diagnosis can reduce the disease mortality caused by the blood stream infection. Bloodstream infections are a time critical medical emergency and should be as urgent as wound care or myocardial infarction with a definite response time. Antibiotic Susceptibility Test (AST) is a currently accepted method for determining bacterial susceptibility to antibiotics by determining the efficacy of antibacterial agents in inhibiting the growth of pathogenic microorganisms in vitro. Therefore, after bacteria are captured, dead bacteria floating in the supernatant are removed by using a density gradient centrifugation method, and in order to achieve the purpose of rapid detection and treatment of blood stream infection, only the fact that a patient has blood stream infection is proved, an antibacterial drug sensitivity test result is rapidly given, then the rapid fluorescence culture of trace broth is directly carried out, and the purpose of purifying the bacteria by picking a single colony for culture is not needed.
At present, the methods for carrying out drug sensitivity tests in clinical microbiological laboratories mainly comprise a paper diffusion method, a dilution method, an antibiotic concentration method, an automatic instrument and the like. Many clinical laboratories use the paper diffusion method as a routine drug susceptibility test, which has the disadvantage of not being suitable for slow growing strains and some fastidious bacteria; the main disadvantage of the dilution method is the cumbersome operation; the cost of the antibiotic concentration method is too high to be suitable for routine test application; automated instruments require instrumentation to perform. These methods have low blood culture positive rate and detection rate for pathogenic bacteria of clinical bloodstream infection, the positive rate is about 9%, the detection rate is about 85%, and blood culture is mainly used for diagnosing bloodstream infection, but the total turnover time of traditional antibacterial drug sensitivity detection of blood samples in positive bloody culture bottles of patients with bloodstream infection is more than three days, because the method needs three overnight culture steps: blood culture, subculture, and antibiotic susceptibility test culture, so that treatment is delayed and contamination by microorganisms is easy. Approximately 30% -50% of blood culture results show negatives in those patients who appear to have an infection. These negative blood cultures may be due to low pathogen counts or the presence of non-culturable infectious agents in the blood samples. And in the positive blood culture bottle, the bacteria are mixed with a large amount of blood cells, and the concentration of the bacteria is within 107To 109CFU/mL, unpredictable. Since conventional AST systems detect changes in the bacterial population by measuring the Optical Density (OD) of antibiotic-administered pathogen cultures, they are very sensitively dependent on the amount of the initial inoculum strain, and the initial concentration of bacteria should be strictly controlled. Therefore, blood culture positive bottles cannot be used directly for antibiotic susceptibility testing using conventional methods, and subculture on agar plates is required to obtain pure strains at accurate concentrations in order to perform an overnight antibiotic susceptibility testing process using bacterial stock. Due to the low detection sensitivity, a certain contamination rate exists, so that the diagnosis and treatment of early blood stream infection are influenced.
Disclosure of Invention
The application provides a blood stream infection pathogenic negative bacteria trace broth fluorescence drug sensitivity method, which aims to solve the problems that the diagnosis and treatment of early blood stream infection are influenced due to low detection sensitivity and certain pollution rate.
The application provides a blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitivity method, which comprises the following steps:
single colonies were picked and grown overnight in medium and subjected to 12 gradient design to test OD of bacterial concentration625A value;
diluting the buffer solution by using sterile deionized water to obtain a diluted buffer solution;
incubating 20 mu L of ApoH magnetic beads, the buffer solution and the cultured colony for 15min at the temperature of 37 ℃ by a bacteria culture shaker at 300rpm to obtain a bacteria-ApoH magnetic bead mixture;
centrifuging the bacterium-ApoH magnetic bead mixture at 12000rpm at 4 ℃, discarding the supernatant and resuspending to obtain a bacterium suspension;
putting the bacterial suspension on an MS separation column to pass through the column to obtain reaction liquid after passing through the column;
the reaction solution was used to perform a 96-well plate fluorescence susceptibility test.
Alternatively, single colonies were picked and grown overnight in medium and subjected to 12 gradient design to test the OD of the bacterial concentration625The values include:
experiment picking single colony of Escherichia coli (ATCC-25922) in an erlenmeyer flask filled with a proper amount of LB broth culture medium, shaking for overnight, wherein the temperature is 37 ℃ and the rotating speed is 180 rpm/min; then, 5mL of physiological saline with the mass fraction of 0.9 percent is used for carrying out gradient design of bacterial colony amount; the colonies added thereto (CFU/mL) were: 1X 109、1.5×108、1×108、1×107、1×106、1×105、1×104、1×103、1×102、1×101、1×100And a 0.9% normal saline control group;
OD for measuring concentration of corresponding bacteria by using multifunctional microplate monitor625The value is obtained.
Optionally, the buffer solution is diluted with sterile deionized water to obtain a diluted buffer solution, which includes diluting the 10 × TTGB-10 buffer solution with sterile deionized water to 2 × TTGB-10 buffer solution.
Optionally, the step of incubating 20 μ L of ApoH magnetic beads, the buffer and the cultured colony for 15min at 37 ℃ in a bacterial shaker at 300rpm to obtain a bacterial-ApoH magnetic bead mixture comprises:
first, the concentration of the bacteria contained in the culture medium (CFU/mL) was 1X 109、1.5×108、1×108、1×107、1×106、1×105、1×104、1×103、1×102、1×101、1×100And 0.9% saline control 5mL of 0.9% saline added 5mL of 2 XTGB-10 buffer, then 20. mu.L of ApoH magnetic beads to each respective tube;
the tube was incubated at 37 ℃ for 15min with a bacterial shaker at 300rpm to obtain a bacterial-ApoH magnetic bead mixture.
Optionally, the step of centrifuging the bacterium-ApoH magnetic bead mixture at 12000rpm at 4 ℃, discarding the supernatant, and resuspending to obtain a bacterial suspension comprises:
centrifuging the bacterium-ApoH magnetic bead mixture at 4 ℃ and 12000rpm for 10min, and removing the supernatant;
resuspending the mixture with the supernatant in 1mL PBS solution with pH 7.4, centrifuging at 12000rpm for 5min under 4 deg.C, and discarding the supernatant;
the suspension after discarding the supernatant was resuspended in 1mL of PBS to obtain a bacterial suspension.
Optionally, the step of placing the bacterial suspension on an MS separation column and passing through the column to obtain a reaction solution after passing through the column comprises:
placing the bacterial suspension on an MS separation column, washing the column by using 1mL of washing buffer solution, wherein the reaction solution contains unlabeled bacteria;
taking out the MS separation column from the separation device, placing the MS separation column into a new centrifuge tube, sucking 1mL of washing buffer solution, and reacting to obtain the required components;
the reaction mixture was centrifuged at 12000rpm at 4 ℃ for 5min, and the supernatant was discarded and then resuspended in 100. mu.L of PBS to obtain a resuspended reaction mixture.
Optionally, the step of performing a 96-well plate fluorescence drug sensitivity test by using the reaction solution includes:
taking out antibiotic powder, dissolving and diluting, adding 200 mu L of antibacterial drug with the concentration of 64 mu g/mL into the first hole of the pore plate, respectively adding 100 mu L of MH broth culture medium into the second hole to the eleventh hole, sucking 100 mu L from the first hole, adding the mixture into the second hole, uniformly mixing, sucking 100 mu L to the third hole, and repeating the steps, sucking 100 mu L from the tenth hole and discarding; the drug concentration in each well is as follows: 128. 64, 32, 16, 8, 4, 2, 1, 0.5 and 0.25. mu.g/mL, 200. mu. LMH broth medium was added to column 11 as a negative control, and 200. mu.L of the reaction solution was added to column 12 as a positive control; wherein the concentration of the reaction solution is 1X 105CFU/mL；
The reaction solution was aspirated and its concentration was adjusted to 1X 10 with MH broth8CFU/mL, diluted 100-fold with MH broth to reach a reaction concentration of 1X 106CFU/mL, adding 100 mu L of CFU/mL into each concave hole in the drug sensitive plate according to 1-10 rows per hole, so that the final bacterial suspension concentration in each hole is 1 multiplied by 105CFU/mL；
Labeling the antibody with a fluorescent kit;
placing the inoculated drug sensitive plate at 37 ℃ and 5% CO2Culturing in an incubator;
the drug sensitive plate is at 37 ℃ and 5% CO2After incubation in an incubator for 10h, 5. mu.L of fluorescent antibody was added to each well and the incubation was continued at 37 ℃ and 5% CO2Incubating in incubator for 30 min;
and (4) detecting the fluorescence intensity by using a multifunctional microplate monitor, and determining the MIC.
According to the technical scheme, the application provides a blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method, which comprises the following steps: single colonies were picked and grown overnight in medium and subjected to 12 gradient design to test OD of bacterial concentration625A value; diluting the buffer solution by using sterile deionized water to obtain a diluted buffer solution; incubating 20 mu L of ApoH magnetic beads, the buffer solution and the cultured colony for 15min at the temperature of 37 ℃ by a bacteria culture shaker at 300rpm to obtain a bacteria-ApoH magnetic bead mixture; centrifuging the bacterium-ApoH magnetic bead mixture at 4 ℃ and 12000rpm, discarding the supernatant and resuspending to obtain a bacterium suspension; placing the bacterial suspension on an MS separation columnPassing through a column to obtain a reaction solution after passing through the column; the reaction solution was used to perform a 96-well plate fluorescence susceptibility test.
According to the method, when pathogenic bacteria infected by blood flow are detected, overnight culture and flat plate purification culture of the blood specimen are not needed after blood collection, and bacteria are enriched from the blood specimen by applying ApoH magnetic beads directly by using the magnetic bead enrichment principle.
When the method is used for detecting the pathogenic bacteria infected by the blood stream, the magnetic bead enrichment principle is utilized for detection, and the magnetic bead enrichment bacteria can improve the detection sensitivity, so that the detection positive rate and the detection rate are improved, and the detection method is improved compared with the traditional antibacterial drug sensitivity detection system.
The method for detecting the pathogenic bacteria of the bloodstream infection is based on the direct magnetic bead enrichment principle, and by applying the combination of the ApoH magnetic beads and the bacteria in the blood sample, only the bacterial infection in the blood sample is detected and the drug sensitive result can be determined, so that the clinical treatment can be carried out, and the antibacterial drug sensitive test can be directly carried out without the need of bacterial purification.
In the process of detecting the blood stream infection pathogenic bacteria by the method provided by the application, the density gradient centrifugation method is utilized to deposit the live bacteria, so that the live bacteria and the dead bacteria are distinguished, and the dead bacteria are removed.
The method provided by the application is used for carrying out the drug sensitivity test of the pathogenic bacteria of the bloodstream infection, and the observation of the drug sensitivity result is easier by observing the change of the fluorescence intensity value.
The total turnover time from blood sampling to antibiotic susceptibility results for detecting bloodstream infection pathogens by the methods provided herein is within about 13 hours; the total turnaround time from positive blood culture to antibiotic susceptibility was approximately 26 h.
Drawings
In order to more clearly explain the technical solution of the present application, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious to those skilled in the art that other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a schematic flow chart of a blood stream infection pathogen negative bacteria broth fluorescence drug sensitivity method provided by the present application;
FIG. 2 is a graph comparing conventional bloodstream infection detection with the methods provided herein.
Detailed Description
Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings. When the following description refers to the accompanying drawings, like numbers in different drawings represent the same or similar elements unless otherwise indicated. The embodiments described in the following examples do not represent all embodiments consistent with the present application. But merely as exemplifications of systems and methods consistent with certain aspects of the application, as recited in the claims.
Referring to fig. 1, a schematic flow chart of a blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitivity method is provided for the present application.
The application provides a blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitivity method, which comprises the following steps:
1, weighing bacteria, putting the bacteria into a culture medium for culture, carrying out 12 gradient designs, and testing the OD of the concentration of the bacteria625A value;
picking a single colony of Escherichia coli (ATCC-25922) in an Erlenmeyer flask containing a proper amount of LB broth for shaking overnight, wherein the temperature is 37 ℃ and the rotating speed is 180 rpm/min; then, 5mL of physiological saline with the mass fraction of 0.9 percent is used for carrying out gradient design of bacterial colony amount; the colonies added thereto (CFU/mL) were: 1X 109、1.5×108、1×108、1×107、1×106、1×105、1×104、1×103、1×102、1×101、1×100And a 0.9% normal saline control group;
OD for measuring concentration of corresponding bacteria by using multifunctional microplate monitor625The value is obtained.
2, diluting the buffer solution by using sterile deionized water to obtain a diluted buffer solution;
diluting the buffer solution with sterile deionized water to obtain diluted buffer solution, wherein the diluting of the 10 XTGB-10 buffer solution to 2 XTGB-10 buffer solution with sterile deionized water is included.
3, incubating 20 mu L of ApoH magnetic beads, the buffer solution and the cultured colony for 15min at the temperature of 37 ℃ by a bacteria culture shaker at 300rpm to obtain a bacteria-ApoH magnetic bead mixture;
firstly, the concentration of the contained bacteria is 1 multiplied by 109、1.5×108、1×108、1×107、1×106、1×105、1×104、1×103、1×102、1×101、1×100And 0.9% saline control 5mL of 2 × TTGB-10 buffer in 0.9% saline, then 20 μ L of ApoH magnetic beads to each respective tube;
the tube was incubated at 37 ℃ for 15min with a bacterial shaker at 300rpm to obtain a bacterial-ApoH magnetic bead mixture.
4, centrifuging the bacterium-ApoH magnetic bead mixture at 4 ℃ and 12000rpm, discarding the supernatant and carrying out resuspension to obtain a bacterium suspension;
centrifuging the bacterium-ApoH magnetic bead mixture at 4 ℃ and 12000rpm for 10min, and removing the supernatant;
resuspending the mixture with the supernatant in 1mL PBS solution with pH 7.4, centrifuging at 12000rpm for 5min under 4 deg.C, and discarding the supernatant;
the suspension after discarding the supernatant was resuspended in 1mL of PBS to obtain a bacterial suspension.
5, placing the bacterial suspension on an MS separation column to pass through the column to obtain a reaction solution after passing through the column;
placing the bacterial suspension on an MS separation column, enabling the liquid to flow down naturally, enabling the reaction liquid to contain unlabeled bacteria, and washing the column by using 1mL of washing buffer liquid;
taking out the MS separation column from the separation device, placing the MS separation column into a new centrifuge tube, sucking 1mL of washing buffer solution, and reacting to obtain the required components;
the reaction mixture was centrifuged at 12000rpm at 4 ℃ for 5min, and the supernatant was discarded and then resuspended in 100. mu.L of PBS to obtain a reaction mixture.
6, a 96-well plate fluorescence drug sensitivity test was performed using the reaction solution.
Taking out antibiotic powder, dissolving and diluting, adding 200 μ L antibacterial agent with concentration of 64 μ g/mL into the first hole of the hole plate, and adding the second to the tenthAdding 100 μ L MH broth into one well, sucking 100 μ L from the first well, adding into the second well, mixing, sucking 100 μ L to the third well, repeating above steps, sucking 100 μ L from the tenth well, and discarding; the drug concentration in each well is as follows: 128. 64, 32, 16, 8, 4, 2, 1, 0.5 and 0.25. mu.g/mL, 200. mu. LMH broth medium was added to column 11 as a negative control, and 200. mu.L of the reaction solution was added to column 12 as a positive control; wherein the concentration of the reaction solution is 1X 105CFU/mL；
The reaction solution was aspirated and its concentration was adjusted to 1X 10 with MH broth8CFU/mL, diluted 100-fold with MH broth to reach a reaction concentration of 1X 106CFU/mL, adding 100 mu L of CFU/mL into each concave hole in the drug sensitive plate according to 1-10 rows per hole, so that the final bacterial suspension concentration in each hole is 1 multiplied by 105CFU/mL；
Labeling the antibody with a fluorescent kit;
placing the inoculated drug sensitive plate at 37 ℃ and 5% CO2Culturing in an incubator;
the drug sensitive plate is at 37 ℃ and 5% CO2After incubation in an incubator for 10h, 5. mu.L of fluorescent antibody was added to each well and the incubation was continued at 37 ℃ and 5% CO2Incubating in incubator for 30 min;
and (3) detecting the fluorescence intensity by using a multifunctional microplate monitor, and determining the MIC (minimum inhibitory concentration).
Examples
Selecting standard strain Escherichia coli ATCC25922 to carry out rapid fluorescence drug sensitivity test of blood stream infection pathogenic negative bacteria trace broth, putting the trace broth drug sensitivity plate inoculated with gentamicin, tetracycline, ciprofloxacin and imipenem into a 35 ℃ incubator to be respectively cultured for 4h, 6h, 8h and 10h, then taking out, adding 5 mu L of Lipid A LPS Polyclonal Antibody (LPS Polyclonal Antibody) (1: 30) marked by Alexa Fluor Protein Labeling Kit (Alexa Fluor 488 Protein Labeling Kit) into each hole, continuously culturing for 30min at 35 ℃, and detecting the fluorescence intensity value by using a multifunctional microplate monitor to determine MIC. The changes of fluorescence intensity values of gentamicin, tetracycline, ciprofloxacin and imipenem drug sensitive holes at different culture time points are shown in table 1, it was found by examination that the fluorescence intensity values of MH broth inoculated with gentamicin, tetracycline, ciprofloxacin and imipenem were substantially gradually decreased from 4h to 10h of incubation until 10h of incubation in an incubator at 35 deg.C, after further incubation for 30min with 5. mu.l of fluorescent antibody, the drug sensitive wells with fluorescence intensity value of 0 mean that no bacteria survive in the drug sensitive wells containing antibiotics, and the fluorescence intensity value is basically gradually reduced along with the increase of the drug concentration, which indicates that the amount of bacteria is gradually reduced, according to CLSIM100 files, the results are sensitive, wherein the MIC of gentamicin is less than or equal to 4 mug/mL, the MIC of tetracycline is less than or equal to 4 mug/mL, the MIC of ciprofloxacin is less than or equal to 1 mug/mL, and the MIC of imipenem is less than or equal to 1 mug/mL.
TABLE 1 statistics of the results of the fluorescence susceptibility test on Escherichia coli ATCC-25922 susceptibility
Figure BDA0002914673010000061
Figure BDA0002914673010000071
According to the technical scheme, the application provides a blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method, which comprises the following steps: single colonies were picked and grown overnight in medium and subjected to 12 gradient design to test OD of bacterial concentration625A value; diluting the buffer solution by using sterile deionized water to obtain a diluted buffer solution; incubating 20 mu L of ApoH magnetic beads, the buffer solution and the cultured colony for 15min at the temperature of 37 ℃ by a bacteria culture shaker at 300rpm to obtain a bacteria-ApoH magnetic bead mixture; centrifuging the bacterium-ApoH magnetic bead mixture at 4 ℃ and 12000rpm, discarding the supernatant and resuspending to obtain a bacterium suspension; putting the bacterial suspension on an MS separation column to pass through the column to obtain reaction liquid after passing through the column; the reaction solution was used to perform a 96-well plate fluorescence susceptibility test.
In order to reduce the total turnaround time (TAT) of the current antibiotic drug resistance detection process, the method mainly aims to process the inoculation strain quantity with a wide dynamic range from a blood culture positive bottle under the condition of no separation and purification culture process to develop a rapid fluorescence drug sensitive system for pathogenic bacteria trace broth of blood stream infection, the total turnaround time from blood culture to antibacterial drug sensitive test is expected to be 27 hours under the condition of not influencing the accuracy of detection results, and the total turnaround time is shortened by 38 hours compared with the total turnaround time of the current clinical traditional antibacterial drug sensitive detection for pathogenic bacteria of blood stream infection; and the MIC is judged by detecting the fluorescence intensity value, so that the method is simpler and more convenient.
When the method is used for detecting the pathogenic bacteria infected by the blood stream, the magnetic bead enrichment principle is utilized for detection, and the magnetic bead enrichment bacteria can improve the detection sensitivity, so that the detection positive rate and the detection rate are improved, and the detection method is improved compared with the traditional antibacterial drug sensitivity detection system.
The method for detecting the pathogenic bacteria of the bloodstream infection is based on the direct magnetic bead enrichment principle, and by applying the combination of the ApoH magnetic beads and the bacteria in the blood sample, only the bacterial infection in the blood sample is detected and the drug sensitive result can be determined, so that the clinical treatment can be carried out, and the antibacterial drug sensitive test can be directly carried out without the need of bacterial purification.
The present application utilizes ApoH magnetic beads to enrich bacteria in a 5mL blood culture flask within 20 minutes (pathogen bound to ApoH magnetic beads for 15min, bead wash for 5min) and also has a detection limit of 1 CFU/mL. In the traditional trace broth dilution method, the pathogenic bacteria and the antibiotics are co-cultured for about 20h, the broth turbidity is observed, and the broth OD value is detected to judge the MIC value, while in the application, the pathogenic bacteria and the antibiotics are quickly co-cultured for 10h, then the fluorescent antibody is added for incubation for 0.5h, the fluorescent antibody is utilized to specifically bind the pathogenic bacteria, and the MIC value is determined by detecting the fluorescence intensity value, so that the time is saved, and the intuition is realized. FIG. 2 is a graph comparing conventional bloodstream infection detection with the methods provided herein. The total turnover time from blood sampling to antibiotic susceptibility results for detecting bloodstream infection pathogens by the methods provided herein is within about 13 hours; the total turnaround time from positive blood culture to antibiotic susceptibility was approximately 26 h.
The embodiments provided in the present application are only a few examples of the general concept of the present application, and do not limit the scope of the present application. Any other embodiments extended according to the scheme of the present application without inventive efforts will be within the scope of protection of the present application for a person skilled in the art.

Claims (7)

1. A blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method is characterized by comprising the following steps:
single colonies were picked and grown overnight in medium and subjected to 12 gradient design to test OD of bacterial concentration625A value;
diluting the buffer solution by using sterile deionized water to obtain a diluted buffer solution;
incubating 20 mu L of ApoH magnetic beads, the buffer solution and the cultured colony for 15min at the temperature of 37 ℃ by a bacteria culture shaker at 300rpm to obtain a bacteria-ApoH magnetic bead mixture;
centrifuging the bacterium-ApoH magnetic bead mixture at 12000rpm at 4 ℃, discarding the supernatant and resuspending to obtain a bacterium suspension;
putting the bacterial suspension on an MS separation column to pass through the column to obtain reaction liquid after passing through the column;
the reaction solution was used to perform a 96-well plate fluorescence susceptibility test.
2. The method of claim 1, wherein the single colony is cultured overnight in a culture medium and subjected to 12 gradient design to test OD of bacteria concentration625The values include:
picking a single colony of Escherichia coli (ATCC-25922) in an Erlenmeyer flask containing a proper amount of LB broth for shaking overnight, wherein the temperature is 37 ℃ and the rotating speed is 180 rpm/min; then, 5mL of physiological saline with the mass fraction of 0.9 percent is used for carrying out gradient design of bacterial colony amount; the colonies added thereto (CFU/mL) were: 1X 109、1.5×108、1×108、1×107、1×106、1×105、1×104、1×103、1×102、1×101、1×100And a 0.9% normal saline control group;
OD for measuring concentration of corresponding bacteria by using multifunctional microplate monitor625The value is obtained.
3. The method of claim 1, wherein diluting the buffer with sterile deionized water to obtain a diluted buffer comprises diluting 10 XTTGB-10 buffer with sterile deionized water to 2 XTTGB-10 buffer.
4. The method of claim 1, wherein the step of incubating 20 μ L ApoH magnetic beads, the buffer solution and the cultured colony for 15min at 37 ℃ on a bacterial shaker at 300rpm to obtain a bacterial-ApoH magnetic bead mixture comprises:
first, the concentration of the bacteria contained in the culture medium (CFU/mL) was 1X 109、1.5×108、1×108、1×107、1×106、1×105、1×104、1×103、1×102、1×101、1×100And 0.9% saline control 5mL of 0.9% saline added 5mL of 2 XTGB-10 buffer, then 20. mu.L of ApoH magnetic beads to each respective tube;
the tube was incubated at 37 ℃ for 15min with a bacterial shaker at 300rpm to obtain a bacterial-ApoH magnetic bead mixture.
5. The method of claim 1, wherein the step of centrifuging the bacterium-ApoH magnetic bead mixture at 12000rpm at 4 ℃, discarding the supernatant, and resuspending the bacterium suspension to obtain the fluorescence sensitivity of the blood stream infection pathogen negative bacteria comprises:
centrifuging the bacterium-ApoH magnetic bead mixture at 4 ℃ and 12000rpm for 10min, and removing the supernatant;
resuspending the mixture with the supernatant in 1mL PBS solution with pH 7.4, centrifuging at 12000rpm for 5min under 4 deg.C, and discarding the supernatant;
the suspension after discarding the supernatant was resuspended in 1mL of PBS to obtain a bacterial suspension.
6. The method for fluorescence susceptibility of blood stream infection pathogen negative bacteria broth as claimed in claim 1, wherein the step of placing the bacterial suspension on an MS separation column and passing the bacterial suspension through the column to obtain the reaction solution after passing through the column comprises:
placing the bacterial suspension on an MS separation column, washing the column by using 1mL of washing buffer solution, wherein the reaction solution contains unlabeled bacteria;
taking out the MS separation column from the separation device, placing the MS separation column into a new centrifuge tube, and sucking 1mL of washing buffer solution;
the reaction mixture was centrifuged at 12000rpm at 4 ℃ for 5min, and the supernatant was discarded and then resuspended in 100. mu.L of PBS to obtain a resuspended reaction mixture.
7. The method for performing fluorescence susceptibility testing on blood stream infection pathogen negative bacteria broth as claimed in claim 1, wherein the 96-well plate fluorescence susceptibility testing step using the reaction solution comprises:
taking out antibiotic powder, dissolving and diluting, adding 200 mu L of antibacterial drug with the concentration of 64 mu g/mL into the first hole of the pore plate, respectively adding 100 mu L of MH broth culture medium into the second hole to the eleventh hole, sucking 100 mu L from the first hole, adding the mixture into the second hole, uniformly mixing, sucking 100 mu L to the third hole, and repeating the steps, sucking 100 mu L from the tenth hole and discarding; the drug concentration in each well is as follows: 128. 64, 32, 16, 8, 4, 2, 1, 0.5 and 0.25. mu.g/mL, 200. mu. LMH broth medium was added to column 11 as a negative control, and 200. mu.L of the reaction solution was added to column 12 as a positive control; wherein the concentration of the reaction solution is 1X 105CFU/mL；
The reaction solution was aspirated and its concentration was adjusted to 1X 10 with MH broth8CFU/mL, diluted 100-fold with MH broth to reach a reaction concentration of 1X 106CFU/mL, adding 100 mu L of CFU/mL into each concave hole in the drug sensitive plate according to 1-10 rows per hole, so that the final bacterial suspension concentration in each hole is 1 multiplied by 105CFU/mL；
Labeling the antibody with a fluorescent kit;
placing the inoculated drug sensitive plate on37 ℃ and 5% CO2Culturing in an incubator;
the drug sensitive plate is at 37 ℃ and 5% CO2After incubation in an incubator for 10h, 5. mu.L of fluorescent antibody was added to each well and the incubation was continued at 37 ℃ and 5% CO2Incubating in incubator for 30 min;
and (4) detecting the fluorescence intensity by using a multifunctional microplate monitor, and determining the MIC.
CN202110096896.8A 2021-01-25 2021-01-25 Blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method Pending CN112725403A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110096896.8A CN112725403A (en) 2021-01-25 2021-01-25 Blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110096896.8A CN112725403A (en) 2021-01-25 2021-01-25 Blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method

Publications (1)

Publication Number Publication Date
CN112725403A true CN112725403A (en) 2021-04-30

Family

ID=75593878

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110096896.8A Pending CN112725403A (en) 2021-01-25 2021-01-25 Blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method

Country Status (1)

Country Link
CN (1) CN112725403A (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100285447A1 (en) * 2009-05-07 2010-11-11 Biomerieux, Inc. Methods for Antimicrobial Resistance Determination
US20150118688A1 (en) * 2012-04-12 2015-04-30 Becton Dickinson And Company Methods, systems, and devices for detecting and identifying microorganisms in microbiological culture samples
WO2017127684A1 (en) * 2016-01-21 2017-07-27 SeLux Diagnostics, Inc. Methods for rapid antimicrobial susceptibility testing
CN110988341A (en) * 2019-12-13 2020-04-10 宁夏医科大学总医院 Rapid fluorescence drug sensitivity detection method of blood stream infection pathogenic bacteria trace broth
CN111088318A (en) * 2020-01-03 2020-05-01 西北农林科技大学 Method for detecting bacterial drug sensitivity by TTC reduction reaction
CN111936633A (en) * 2018-04-03 2020-11-13 动力生物科学有限公司 Microbial isolation and detection

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100285447A1 (en) * 2009-05-07 2010-11-11 Biomerieux, Inc. Methods for Antimicrobial Resistance Determination
US20150118688A1 (en) * 2012-04-12 2015-04-30 Becton Dickinson And Company Methods, systems, and devices for detecting and identifying microorganisms in microbiological culture samples
WO2017127684A1 (en) * 2016-01-21 2017-07-27 SeLux Diagnostics, Inc. Methods for rapid antimicrobial susceptibility testing
CN111936633A (en) * 2018-04-03 2020-11-13 动力生物科学有限公司 Microbial isolation and detection
CN110988341A (en) * 2019-12-13 2020-04-10 宁夏医科大学总医院 Rapid fluorescence drug sensitivity detection method of blood stream infection pathogenic bacteria trace broth
CN111088318A (en) * 2020-01-03 2020-05-01 西北农林科技大学 Method for detecting bacterial drug sensitivity by TTC reduction reaction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MANJULA RAMYAVUTUKURU等: "A rapid, highly sensitive and culture-free detection of pathogens from blood by positive enrichment", 《JOURNAL OF MICROBIOLOGICAL METHODS》 *

Similar Documents

Publication Publication Date Title
Sabiston Jr et al. Bacterial study of pyogenic infections of dental origin
Kanchana et al. Evaluation of the BACTEC™ MGIT™ 960 system for the recovery of mycobacteria
WO2020233148A1 (en) Inert carrier salmonella sp. and potential application thereof
Akter et al. Comparative evaluation of chromogenic agar medium and conventional culture system for isolation and presumptive identification of uropathogens
WO2020233147A1 (en) Inert carrier escherichia coli and potential use thereof
Wong et al. A chemically defined liquid medium that supports primary isolation of Rochalimaea (Bartonella) henselae from blood and tissue specimens
Tajbakhsh et al. Identification of Streptococcus agalactiae by fluorescent in situ hybridization compared to culturing and the determination of prevalence of Streptococcus agalactiae colonization among pregnant women in Bushehr, Iran
CN108362629B (en) Rapid detection method and kit for single viable bacteria of Escherichia coli O157H 7
Nerbrand et al. Are current rapid detection tests for Group A Streptococci sensitive enough? Evaluation of 2 commercial kits
EP0496345B1 (en) Method for detecting and quantifying cariogenic bacteria
CN1888076A (en) Fast identification method for ox tubercle bacillus and its drug sensitive test kit
CN112725403A (en) Blood stream infection pathogen negative bacteria trace broth fluorescence drug sensitization method
Tuncer et al. Comparison of cytochemical staining, immunofluorescence and PCR for diagnosis of Pneumocystis carinii on sputum samples
Jousimies-Somer et al. Problems encountered in clinical anaerobic bacteriology
JP2016168058A (en) Disk test specimen for detecting drug-resistant bacterium
Thewessen et al. Comparison of HeLa 229 and McCoy cell cultures for detection of Chlamydia trachomatis in clinical specimens
CN101824462B (en) Quantitative detection method of campylobacter in food
CN115261439A (en) Helicobacter pylori drug sensitivity kit and detection method thereof
Wren Clostridium difficile isolation and culture techniques
Riley Principles of microscopy, culture and serology-based diagnostics
Salzman et al. Current and experimental methods of rapid microbial identification
Ber et al. Enrichment of Yersinia pestis from blood cultures enables rapid antimicrobial susceptibility determination by flow cytometry
Li et al. Bacteremia Caused by Turicella otitidis in a Patient with Diffuse Large B-Cell Lymphoma.
RU2729575C1 (en) Method for identification of cholera vibrio o1 serogroups of biovars classical and el tor
RU2281501C1 (en) METHOD FOR QUICK-TEST DETECTING OF INTRA-HOSPITAL Burkholderia cepacia INFECTION AND ITS DIFFERENTIATION AGAINST OTHER SPECIES OF BURKCHOLDERIA AND PSEUDOMONAS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210430

RJ01 Rejection of invention patent application after publication